Arpeggio is excited to announce Kevin Eastwood joining as CBO, bringing more than 25 years of experience at innovative pharmaceutical and therapeutics companies across the nation.

Arpeggio presented two exciting posters sharing updates on our GPX4 inhibitor and announcing our NRF2 degrader leading to regression of aggressive adenocarcinoma tumors in vivo.

We've discovered a novel NRF2 pathway inhibitor with significant activity in KEAP1-mutant lung adenocarcinomas.

Our first-in-class GPX4 inhibitor is leading to extremely significant tumor growth inhibition in multiple mouse models of cancer.

We've discovered a targeted Ferroptosis blocker that prevents renal injury in mice.

AstraZeneca just put out a great new review looking at the current-state-of-the-art for finding covalent small molecules. We routinely screen cysteine-focused covalent small molecules at Arpeggio because of their massive transcriptional-impact diversity. This review helps us put our chemotranscriptomic platform within the context of other exciting and emerging technologies!

Arpeggio is selected as a finalist for the Rising Star of the Year Award by the Colorado BioScience Association.

A nice new atlas from Li et al. performed a massively parallel drop-out screen for many cysteines in known oncogenic genes. This dataset will help pave the way for covalent drug discovery in oncology and the potential target landscape!

Arpeggio Co-Founders Laura Norris and Joey Azofeifa are recognized as emerging business leaders in Boulder Valley.

We presented two posters at AACR describing how high-throughput transcriptomics is helping to identify novel GPX4 inhibitors.

In collaboration with Forma Therapeutics, Arpeggio uses their transcriptional platform to uncover novel mechanisms of CBP inhibitors.

An exciting paper from Ryan et al. shows that inhibition of SEC24B may be a new mechanism to prevent ferroptosis in microglia and potentially bring a completed new treatment for neurodegenerative indications like Parkinson’s.

A feature on Arpeggio and our mission to bring new medicine to patients with cancer and rare disease.

Arpeggio featured in a great write up by Paul Schloesser on how we're building our drug pipeline and discovery platform.

We have partnered with Builders VC, and many returning investors, to develop our pipeline of transcriptomic medicine.

We were selected to pitch at Destination Startup Ventures 2021, a showcase featuring the best companies from across the Rocky Mountain Region.

This Nature paper from Kim et al. illuminates a really exciting mechanism underpinning chronic kidney disease and ferroptosis. In patients with type 2 diabetes, nephrons had significantly lower levels of ferroptosis-defense enzymes like GPX4 and system-xc, this predisposes type 2 diabetes patients to accelerated chronic kidney disease. They go on to show that kidney disease can be halted, and even reversed, in preclinical diabetic nephropathy mouse models with anti-ferroptosis agents.

Arpeggio was featured in the Colorado BioScience Association’s annual publication: “Arpeggio Biosciences: Fusing Big Data With Molecular Biology”

Visualizing and watching changes in transcription.

Arpeggio announces: "Arpeggio Bio raises $3.2 million in seed funding and CEO named to the 2020 Forbes 30 Under 30 list in healthcare"

We took MCF7 cells, treated them with Estradiol and collected nascent RNA every 15 minutes for 6 hours. This is what happened.

Separating correlation and causation from dense time series data in genomics.

We’ve been reading this paper by Wang et al. published in Nature where they show that secretion of IFN-y by CD8+ T-cells sensitizes cells to ferroptosis. This is particularly exciting as it might mechanistically pave the way for a rational combination of ferroptosis inducers and checkpoint-blockade compounds in tumors that don’t normally respond to blockbuster drugs like Keytruda.

Forma Therapeutics announces partnership with Arpeggio: “Celgene-partnered Forma teams with Arpeggio to understand drug-target interactions”